Xenon Pharmaceuticals (XENE) Income towards Parent Company: 2013-2025

Historic Income towards Parent Company for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Income towards Parent Company fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$248.2 million for FY2024, which is 36.07% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Income towards Parent Company is -$90.9 million, which was down 7.31% from -$84.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Income towards Parent Company ranged from a high of -$15.4 million in Q3 2021 and a low of -$90.9 million during Q3 2025.
  • In the last 3 years, Xenon Pharmaceuticals' Income towards Parent Company had a median value of -$57.9 million in 2024 and averaged -$61.0 million.
  • Data for Xenon Pharmaceuticals' Income towards Parent Company shows a maximum YoY tumbled of 12,533.71% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Income towards Parent Company stood at -$25.6 million in 2021, then plummeted by 46.45% to -$37.4 million in 2022, then dropped by 19.51% to -$44.7 million in 2023, then plummeted by 77.77% to -$79.5 million in 2024, then crashed by 44.76% to -$90.9 million in 2025.
  • Its Income towards Parent Company stands at -$90.9 million for Q3 2025, versus -$84.7 million for Q2 2025 and -$65.0 million for Q1 2025.